Kineret — CareFirst (Caremark)

Reauthorization criteria

• Member achieves or maintains a positive clinical response as evidenced by decreased recurrence of pericarditis or improvement in signs and symptoms, demonstrated by improvement in any of the following: pericarditic or pleuritic chest pain, pericardial or pleural rubs, electrocardiogram (ECG), pericardial effusion, or C-reactive protein (CRP).

Approval duration

12 months